3 days Ago By ABMN Staff
Sensus Healthcare ( NASDAQ:SRTS – Free Report ) had its price target hoisted by Maxim Group from $12.00 to $14.00 in a research report sent to investors on Friday, Marketbeat.
com reports. The firm currently has a buy rating on the stock. Separately, HC Wainwright reissued a “buy” rating and set a $10.
00 price target on shares of Sensus Healthcare in a research note on Monday, August 12th. Get Our Latest Analysis on SRTS Sensus Healthcare Price Performance Institutional Investors Weigh In On Sensus Healthcare A number of institutional investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP boosted its holdings in shares of Sensus Healthcare by 128.
0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 166,590 shares of the company’s stock valued at $888,000 after purchasing an additional 93,511 shares during the last quarter. Chapin Davis Inc.
acquired a new position in Sensus Healthcare in the second quarter valued at $53,000. Renaissance Technologies LLC grew its position in Sensus Healthcare by 34.4% during the second quarter.
Renaissance Technologies LLC now owns 391,534 shares of the company’s stock valued at $2,087,000 after acquiring an additional 100,294 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in Sensus Healthcare during the second quarter worth about $156,000. Finally, Sachetta LLC raised its holdings in shares of Sensus Healthcare by 12.
9% in the 2nd quarter. Sachetta LLC now owns 118,354 shares of the company’s stock worth $631,000 after purchasing an additional 13,544 shares during the period. 25.
30% of the stock is currently owned by hedge funds and other institutional investors. About Sensus Healthcare ( Get Free Report ) Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices.
It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. See Also Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter .
.
